Pharmacologic DOT1L inhibition reduces cellular H3K79me2 and suppresses proliferation of DNMT3A-mutant human AML cell lines. (A) Immunoblot analysis of cellular H3K79me2 in OCI AML2 and OCI AML3 cells after treatment with 3 μM EPZ004777. Fraction of H3K79me2/total H3 relative to DMSO-treated control is indicated below each lane. (B) Growth curves of HL60, MV411, OCI AML2, and OCI AML3 cells treated with 3 μM EPZ004777 or vehicle control for 14 days. Numbers are plotted on logarithmic scale. Assays were done in triplicate. Error bars represent standard deviation.